Biden’s Action on Drug Pricing Set for Legal Battles in 2024

The pharmaceutical industry’s resistance to the Biden administration’s program for lowering what Medicare pays for costly drugs is expected to broaden this year, though resolution is unlikely as different lawsuits wind their way through several courts.

Merck & Co., Bristol-Myers Squibb, and Johnson & Johnson are among the drugmakers that have sued President Joe Biden’s Health and Human Services Department to stop the Medicare drug price negotiation program. The HHS has selected 10 drugs for negotiations, with the process slated to continue into 2024. Court watchers say there could be new lawsuits or amendments to existing litigation, much ...